Investment analysts at StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL – Get Rating) in a research report issued on Saturday. The firm set a “sell” rating on the medical technology company’s stock.
Several other equities analysts have also recently commented on BIOL. Colliers Securities reissued a “buy” rating on shares of BIOLASE in a research report on Tuesday, March 22nd. Lake Street Capital started coverage on shares of BIOLASE in a research note on Friday, May 20th. They set a “buy” rating and a $12.00 price target for the company. Finally, Maxim Group started coverage on shares of BIOLASE in a research note on Friday, March 18th. They issued a “buy” rating and a $37.50 price objective for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $41.50.
Shares of BIOL opened at $4.56 on Friday. BIOLASE has a 52 week low of $3.30 and a 52 week high of $23.49. The stock has a market capitalization of $28.15 million, a price-to-earnings ratio of -2.21 and a beta of 1.63. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.22 and a current ratio of 3.34. The stock has a fifty day moving average of $7.54 and a 200-day moving average of $8.77.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley bought a new position in shares of BIOLASE in the first quarter worth approximately $34,000. Jane Street Group LLC bought a new position in BIOLASE in the third quarter worth approximately $26,000. Credit Suisse AG purchased a new stake in shares of BIOLASE in the third quarter worth $29,000. Acadian Asset Management LLC purchased a new stake in shares of BIOLASE in the fourth quarter worth $31,000. Finally, Citadel Advisors LLC increased its stake in shares of BIOLASE by 334.0% in the third quarter. Citadel Advisors LLC now owns 87,626 shares of the medical technology company’s stock worth $56,000 after purchasing an additional 67,437 shares in the last quarter. Institutional investors own 11.38% of the company’s stock.
BIOLASE Company Profile (Get Rating)
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.
- Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
- Palo Alto Networks: Pioneering AI in Cybersecurity
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.